title: The University of California at Los Angeles experience in heart transplantation.
abstract: In the last decade, the number of patients undergoing heart transplant has steadily increased as a result of expanding indications for this procedure. The limitation on the number of transplants performed has been the number of donor organs available. At UCLA, 900 heart transplant procedures have been performed from 1984-1998. Since 1991, the percent of patients free from rejection and infection in the first year after transplant was 70% and 73%, respectively. Actuarial one-, 3-, and 5-year survival rates are 84%, 76%, and 72%, respectively. Survival of patients aged 60 years and over (n = 105) was comparable to that of patients under age 60. We have been pursuing corticosteroid-free immunosuppression, which has led to a decrease in infection complications. Our work with pravastatin early after transplantation has led to a decrease in clinically severe rejection episodes, which has translated into improved survival. Pravastatin also appears to decrease the development of transplant coronary artery disease and appears to have an adjunct immunosuppressive effect in our heart transplant patients on CsA-based immunosuppression. We have also demonstrated benefit of cardiac rehabilitation early after transplant which should therefore be considered as standard postoperative care. Finally, we have participated and led the multicenter mycophenolate study in demonstrating this drug's effectiveness in improved outcomes in primary heart transplant recipients. Future studies include the use of Rapamycin and interleukin-2 receptor blockers which have been demonstrated in kidney transplantation to significantly reduce rejection. Our program is committed to seek better ways to improve outcome and the quality of life of our heart transplant patients.
authors.affiliation: Division of Cardiothoracic Surgery, UCLA School of Medicine, USA.
authors.forename: J A
authors.initials: JA
authors.lastname: Kobashigawa
authors.forename: H
authors.initials: H
authors.lastname: Laks
authors.forename: D
authors.initials: D
authors.lastname: Marelli
authors.forename: J D
authors.initials: JD
authors.lastname: Moriguchi
authors.forename: M A
authors.initials: MA
authors.lastname: Hamilton
authors.forename: G
authors.initials: G
authors.lastname: Fonarow
authors.forename: A
authors.initials: A
authors.lastname: Hage
authors.forename: N
authors.initials: N
authors.lastname: Kawata
mesh_terms: D000328:Adult; D000367:Age Factors; D000924:Anticholesteremic Agents / Q000627:therapeutic use; D005260:Female; D006085:Graft Survival; D016027:Heart Transplantation / Q000401:mortality / Q000502:physiology / Q000706:statistics & numerical data*; D006785:Hospitals, University / Q000706:statistics & numerical data; D006801:Humans; D006937:Hypercholesterolemia / Q000188:drug therapy / Q000209:etiology; D015141:Los Angeles; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications; D017035:Pravastatin / Q000627:therapeutic use; D012189:Retrospective Studies; D015996:Survival Rate; D014019:Tissue Donors / Q000706:statistics & numerical data*; D014850:Waiting Lists
chemical_list: D000924:Anticholesteremic Agents; D017035:Pravastatin